Opening book details…
Can I read Switching to Brolucizumab from Aflibercept in Age-related Macular Degeneration with Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy: an 18-Month Follow-up Study on EtoBox?
Switching to Brolucizumab from Aflibercept in Age-related Macular Degeneration with Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy: an 18-Month Follow-up Study by Tomoko Ueda-Consolvo; Aya Tanigichi; Ayaka Numata; Toshihiko Oiwake; Tomoko Nakamura; Masaaki Ishida; Shuichiro Yanagisawa; Atsushi Hayashi is a Medicine article available to read on EtoBox.
What is Switching to Brolucizumab from Aflibercept in Age-related Macular Degeneration with Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy: an 18-Month Follow-up Study about?
## Purpose: To assess the effect of switching to brolucizumab from aflibercept on eyes with type 1 macular neovascularization (mnv) and polypoidal choroidal vasculopathy (pcv) at 18 months. ## Methods: This study was a retrospective, observational case series that included 19 eyes of 19 patients with type 1mnv and 23 eyes of 22 patients with pcv. we compared the injection intervals, visual acuity, total lesion size, and the number of polypoidal lesions between baseline and 18 months. the correlations between the data including treatment interval, total lesion size, and the number of polyps were also assessed. ## Results: Treatment intervals were significantly extended; from 7.4 ± 1.4 weeks to 11.6 ± 2.6 weeks for type 1 mnv, p < 0.001; from 6.9 ± 1.3 to 11.7 ± 3.1 weeks for pcv, p < 0.001. in type 1 mnv eyes, strong correlation was found between total lesion size and brolucizumab injection intervals (r = - 0.81; p = 0.0002) and moderate correlation was found between treatment frequency with aflibercept and that with brolucizumab (r = 0.76; p = 0.040). in pcv eyes, we found strong correlation between the number of polyps and brolucizumab treatment frequency (r = - 0.81; p = 0.0016
Who reads Switching to Brolucizumab from Aflibercept in Age-related Macular Degeneration with Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy: an 18-Month Follow-up Study?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Tomoko Ueda-Consolvo; Aya Tanigichi; Ayaka Numata; Toshihiko Oiwake; Tomoko Nakamura; Masaaki Ishida; Shuichiro Yanagisawa; Atsushi Hayashi
- Publisher
- Springer Science and Business Media LLC
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)